Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1489 - 1496 of 12089 results

Tackling Healthcare AI's Bias, Regulatory And Inventorship Challenges
August 29, 2023| News

EPA Narrows 'Waters Of The US' Definition To Align With Supreme Court Decision
August 29, 2023| News

Fifth Circuit Court of Appeals Adopts Updated Standard for Pleading Title VII Claims
August 28, 2023| Blog| Viewpoint

CPSC Final Rule for Button Cell and Coin Batteries is Imminent – But Packaging Requirement is Effective Now
August 28, 2023| Blog| Viewpoint

Employers Need To Go Further To Accommodate an Employee’s Religion
August 28, 2023| News

Citing Liability Concerns, Utilities Seek Delay Of Additional CERCLA Rules
August 28, 2023| News

Lawsuits, Tax Fuel Doubt As Medicare Preps Drug Pricing Talks
August 25, 2023| News

Environmental, Social, And Governance Issues In The Securities Litigation Space
August 24, 2023| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
